Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study
Abstract The lack of biomarkers to monitor and predict the efficacy of electroconvulsive therapy (ECT) has hindered its optimal use. To establish metabolomic markers for monitoring and predicting the treatment efficacy of ECT, we comprehensively evaluated metabolite levels in patients with major dep...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2023-08-01
|
| Series: | Scientific Reports |
| Online Access: | https://doi.org/10.1038/s41598-023-40498-7 |
| _version_ | 1797453122724954112 |
|---|---|
| author | Takahito Uchida Yuki Sugiura Eiji Sugiyama Rae Maeda Kenji F. Tanaka Makoto Suematsu Masaru Mimura Hiroyuki Uchida |
| author_facet | Takahito Uchida Yuki Sugiura Eiji Sugiyama Rae Maeda Kenji F. Tanaka Makoto Suematsu Masaru Mimura Hiroyuki Uchida |
| author_sort | Takahito Uchida |
| collection | DOAJ |
| description | Abstract The lack of biomarkers to monitor and predict the efficacy of electroconvulsive therapy (ECT) has hindered its optimal use. To establish metabolomic markers for monitoring and predicting the treatment efficacy of ECT, we comprehensively evaluated metabolite levels in patients with major depressive disorder (MDD) by performing targeted and non-targeted metabolomic analyses using plasma samples before and after the first, third, and final ECT sessions, and 3–7 days after the final session. We compared the plasma metabolomes of age- and sex-matched healthy controls (HCs). Thirteen hospitalized patients with MDD and their corresponding HCs were included in this study. We observed that patients with MDD exhibited lower levels of amino acids, including gamma-aminobutyric acid (GABA), and metabolites involved in tryptophan metabolism and the kynurenine pathway, and higher levels of cortisol at baseline. Furthermore, we investigated the relationship between metabolite levels and depression severity across seven measurement timepoints along with one correlation analysis and found that amino acids, including GABA and tryptophan catabolites, were significantly correlated with the severity of depression. Despite the exploratory nature of this study due to the limited sample size necessitating further validation, our findings suggest that the blood metabolic profile has potential as a biomarker for ECT. |
| first_indexed | 2024-03-09T15:18:22Z |
| format | Article |
| id | doaj.art-357e1c150bb74e01bb081ff18a5e29db |
| institution | Directory Open Access Journal |
| issn | 2045-2322 |
| language | English |
| last_indexed | 2024-03-09T15:18:22Z |
| publishDate | 2023-08-01 |
| publisher | Nature Portfolio |
| record_format | Article |
| series | Scientific Reports |
| spelling | doaj.art-357e1c150bb74e01bb081ff18a5e29db2023-11-26T12:57:41ZengNature PortfolioScientific Reports2045-23222023-08-0113111010.1038/s41598-023-40498-7Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot studyTakahito Uchida0Yuki Sugiura1Eiji Sugiyama2Rae Maeda3Kenji F. Tanaka4Makoto Suematsu5Masaru Mimura6Hiroyuki Uchida7Department of Neuropsychiatry, Keio University School of MedicineDepartment of Biochemistry and Integrative Medical Biology, Keio University School of MedicineDepartment of Analytical and Bioanalytical Chemistry, School of Pharmaceutical Sciences, University of ShizuokaMultiomics Platform, Center for Cancer Immunotherapy and Immunobiology, Kyoto University Graduate School of MedicineDepartment of Neuropsychiatry, Keio University School of MedicineDepartment of Biochemistry and Integrative Medical Biology, Keio University School of MedicineDepartment of Neuropsychiatry, Keio University School of MedicineDepartment of Neuropsychiatry, Keio University School of MedicineAbstract The lack of biomarkers to monitor and predict the efficacy of electroconvulsive therapy (ECT) has hindered its optimal use. To establish metabolomic markers for monitoring and predicting the treatment efficacy of ECT, we comprehensively evaluated metabolite levels in patients with major depressive disorder (MDD) by performing targeted and non-targeted metabolomic analyses using plasma samples before and after the first, third, and final ECT sessions, and 3–7 days after the final session. We compared the plasma metabolomes of age- and sex-matched healthy controls (HCs). Thirteen hospitalized patients with MDD and their corresponding HCs were included in this study. We observed that patients with MDD exhibited lower levels of amino acids, including gamma-aminobutyric acid (GABA), and metabolites involved in tryptophan metabolism and the kynurenine pathway, and higher levels of cortisol at baseline. Furthermore, we investigated the relationship between metabolite levels and depression severity across seven measurement timepoints along with one correlation analysis and found that amino acids, including GABA and tryptophan catabolites, were significantly correlated with the severity of depression. Despite the exploratory nature of this study due to the limited sample size necessitating further validation, our findings suggest that the blood metabolic profile has potential as a biomarker for ECT.https://doi.org/10.1038/s41598-023-40498-7 |
| spellingShingle | Takahito Uchida Yuki Sugiura Eiji Sugiyama Rae Maeda Kenji F. Tanaka Makoto Suematsu Masaru Mimura Hiroyuki Uchida Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study Scientific Reports |
| title | Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study |
| title_full | Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study |
| title_fullStr | Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study |
| title_full_unstemmed | Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study |
| title_short | Metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy: a pilot study |
| title_sort | metabolites for monitoring symptoms and predicting remission in patients with depression who received electroconvulsive therapy a pilot study |
| url | https://doi.org/10.1038/s41598-023-40498-7 |
| work_keys_str_mv | AT takahitouchida metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy AT yukisugiura metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy AT eijisugiyama metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy AT raemaeda metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy AT kenjiftanaka metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy AT makotosuematsu metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy AT masarumimura metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy AT hiroyukiuchida metabolitesformonitoringsymptomsandpredictingremissioninpatientswithdepressionwhoreceivedelectroconvulsivetherapyapilotstudy |